stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) EV/FCF
As of 6 November 2026, Arcutis Biotherapeutics, Inc. (ARQT) trades at a EV/FCF of 71.5×. Over the past ten years it has ranged from −175× (January 2026) to 303× (June 2026); the current reading is higher than 91% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −168× | — |
| FY2024 | −13.3× | — |
| FY2023 | −0.7× | — |
| FY2022 | −2.2× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 74.1× | (45.83%) |
| Jun 2026 | 137× | (47.27%) |
| Mar 2026 | 259× | — |
| Dec 2025 | −168× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR compare | −29.1× |
| EWTX Edgewise Therapeutics, Inc. compare | −23.6× |
| ABCL AbCellera Biologics Inc. compare | −23.4× |
| DNTH Dianthus Therapeutics, Inc. compare | −22.5× |
| TNGX Tango Therapeutics, Inc. compare | −15.0× |
| IOVA Iovance Biotherapeutics, Inc. compare | −14.9× |
| DFTX Definium Therapeutics, Inc. compare | −13.9× |
| RLAY Relay Therapeutics, Inc. compare | −12.0× |
| ARQT Arcutis Biotherapeutics, Inc. | 76.5× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ARQT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement